Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about a recent article by Zhengming Chen et al, published in American Journal of Hematology:
“How does a patient’s risk of relapse change after achieving remission in DLBCL?
A new study developed and externally validated a conditional event-free survival (cEFS) model that dynamically estimates the risk of lymphoma recurrence after completion of frontline therapy, incorporating both baseline characteristics and the length of time a patient has remained in remission.
Key findings:
- Developed using data from 2,757 patients across observational cohorts and randomized clinical trials
- Uses only four readily available clinical variables: • Age • ECOG performance status • Ann Arbor stage • LDH level
- Maintained predictive performance in an independent external validation cohort
- C-index: 0.65 in the development cohort and 0.64 in external validation
Unlike traditional prognostic models that estimate risk at diagnosis, this approach recognizes that relapse risk evolves over time. As patients remain event-free longer, their future risk profile changes, enabling more personalized prognostic counseling.
Beyond informing surveillance strategies, dynamic risk prediction tools may help patients make important life decisions—including family planning, career planning, and long-term financial decisions—with greater confidence.
This represents an important step toward more individualized survivorship care in diffuse large B-cell lymphoma.”
Title: Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
Authors: Zhengming Chen, Danny Luan, Rasmus Rask Kragh Jørgensen, Lasse Jakobsen, Matthew J. Maurer, Tarec C. El-Galaly, Loretta J. Nastoupil, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Izidore S. Lossos, Deborah M. Stephens, Jonathon Cohen, Thomas M. Habermann, Grzegorz Nowakowski, Nancy Bartlett, Jonathan W. Friedberg, Brad S. Kahl, John P. Leonard, Peter Brown, Karin E. Smedby, Mats Jerkeman, Peter Martin
Read the Full Article on American Journal of Hematology
More posts featuring Yan Leyfman